Vacuna cubana en fase 1 de ensayo.
Havana, Aug 24 (RHC) The first Cuban vaccine candidate against Covid-19 in the category of FR (Front Runner), and identified by the acronym Finlay-FR-1, entered Monday the phase of clinical trials in humans.
According to the scientific community of the Caribbean island, the second phase of this process is programmed until September 11, when the 676 volunteers will be completed.
The vaccine candidate - with commercial name Soberana 01 - is the result of the experience accumulated by Cuba in preventive medicine, massive immunization and the development of its biopharmaceutical industry, which today exhibits a well earned international reputation.
Cuba currently administers 11 vaccines (eight of national production), with an average of four million 800 thousand annual doses of simple or combined immunogens that protect against 13 diseases, and every year it exceeds 98 percent coverage in the whole nation, which provides the population with a high level of immunity.